Even Viatris' own forecast doesn't project much revenue growth for the next four years. For more than 150 years, we have worked to make a difference for all who rely on us. P fizer’s legacy-drug business Upjohn will merge with the generic-drug company Mylan to create a new company called Viatris this year. The new company doesn't pay a dividend yet. Get the latest Viatris (VTRS) stock price quote with real-time news, financials, charts and other important investing information. Viatris (VTRS) will begin trading on November 17, 2020. We routinely post information that may be important to investors on our website at www.Pfizer.com. And the stock has now started on trading on Nasdaq under the Ticker Symbol: VTRS. However, Viatris has committed to initiating a dividend program in its first full quarter of operations. The combined company was renamed “Viatris” in connection with the closing. Last week, the big drugmaker completed its merger of Upjohn with Mylan. This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. Spin-offs with Insider Buying (December 2020) Starting today, I will be publishing a monthly article looking at spin-offs with insider buying. Nov 16, 2020 7:59AM EST (RTTNews) - Pfizer Inc. (PFE) has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. The transaction created a new entity, Viatris (NASDAQ:VTRS), that's a leader in branded and generic drugs and biosimilars. Anyone in Seattle/PNW, or willing to relocate there, potential job opening at $280mn AUM L/S value fund. As part of this spinoff, holders of PFE stock will receive 0.124079 shares of VTRS for every 1 share of PFE owned on the date of record, November 13th, 2020. 212-733-8917 Following the distribution of the Upjohn business and its combination with Mylan to form Viatris, historical contributions from the Upjohn business will be treated as a discontinued operation. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We’re motley! Reports are available for download from our Financials and Filings page or at www.sec.gov , or at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. It was a dividend paid in stock instead of cash. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. @themotleyfool #stocks $VTRS $PFE, the deal was great news for Pfizer shareholders, The Most Wildly Undervalued Large-Cap Stock on the Market, 3 Great Dividend Stocks That Are Simply Too Cheap to Ignore, Copyright, Trademark and Patent Information. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. More information on the spin-off can be found here . Cumulative Growth of a $10,000 Investment in Stock Advisor, Should Pfizer Shareholders Sell Their Viatris Stock? Based on where things stand right now, Viatris could offer a dividend yield of more than 5%. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Many great investors advocate investing in stock spin-offs including Peter Lynch. If you owned Pfizer shares prior to the close of the deal, you now also own roughly 0.124079 shares of Viatris for every one share of Pfizer common stock held. Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders … Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments. https://www.businesswire.com/news/home/20201116005378/en/, Media Relations You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning. The board of directors at ‘diversified’ health care REIT operator Ventas (VTR) approved the spinoff of its acute care and skilled nursing facilities into a new REIT named Care Capital Properties. Original Poster 3 months ago. Pfizer's spinoff of Upjohn will happen at the close of business on Nov. 13, 2020, with the merger of Upjohn and Mylan closing three days … About Pfizer: Breakthroughs That Change Patients’ Lives. View source version on businesswire.com: Full time role with possible trial period. My view was that the deal was great news for Pfizer shareholders. As of 18th November its trading at $16.06 a share (-1.71% down on the day) and with a market cap of 8.73 billion. You can benefit from Pfizer's renewed growth and continued strong dividends plus Viatris' even juicier dividends. How can I get copies of financial documents, such as 10-Q and 10-K? Stock analysis for Vtorresource PJSC (VTRS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Pfizer Inc. (PFE) has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. I've been a fan of the Upjohn-Mylan merger for quite a while. The combined company was renamed Viatris in connection with the closing. Piper Sandler doesn’t expect the stock … Or does holding make more sense for now? Viatris (Nasdaq: VTRS) will begin trading tomorrow, November 17, 2020. It will soon provide a really attractive dividend. Pfizer's (NYSE:PFE) long-awaited deal is finally done. View VTRS's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. Share your opinion and gain insight from other stock traders and investors. If you're looking for growth, selling the pharma stock makes sense. Looking ahead at the new Pfizer, we believe our pipeline has never been stronger, and we are energized and inspired to continue developing breakthrough treatments and delivering innovative, life-changing medicines to patients around the world.”. That's not a bad combination at all. Investors who want tremendous growth won't like Viatris. 212-733-7410 As previously announced, Pfizer will retain its Meridian business while the Japan generics collaboration with Mylan will become a part of Viatris following closing, subject to receipt of the required regulatory approval and other customary closing conditions. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Viatris also faces other headwinds. In addition to the Viatris shares received in the distribution, Pfizer stockholders retained as of the closing the same number of shares of Pfizer common stock as they held immediately prior to the transaction. Stock Advisor launched in February of 2002. The Viatris spinoff … Either type of investor should be aware of a few things that typically happen to stock prices after a spinoff. These filings contain important information regarding the risks of investing in our stock. Getting to Know CPO Dara Richardson-Heron, M.D. Pfizer has not updated any components of the 2020 financial guidance provided in its third quarter earnings release, issued on October 28, 2020. Pfizer common stock "ex-distribution” market (NYSE: PFE WI): If a Pfizer stockholder sells shares of Pfizer common stock in the "ex-distribution” market, which will … NOTE: As of 11/20/20, these steps are only for Pfizer Shareholders. Pfizer common stock “ex-distribution” market (NYSE: PFE WI): If a Pfizer stockholder sells shares of Pfizer common stock in the “ex-distribution” market, which will … QQQ 312.83. A high-level overview of Viatris Inc. (VTRS) stock. Market data powered by FactSet and Web Financial Group. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; the impact of COVID-19 on our business, operations and financial results; and competitive developments. Viatris (Nasdaq: VTRS) will begin trading tomorrow, November 17, 2020. PFE spinoff of VTRS, 11/17/2020, 0.124079 VTRS/PFE, non-taxable, 94.8% Remaining basis ROL Stock Split, 3/2, 12/11/2020 SNX spinoff of CNXC, 12/1/2020, 1 … Find the latest Viatris Inc. (VTRS) stock discussion in Yahoo Finance's forum. The following transcript contains forward-looking statements about our anticipated future financial performance that involve substantial risks and uncertainties. This release contains forward-looking information about the completion of the transaction which spun off Pfizer’s Upjohn Business and combined it with Mylan N.V. to form Viatris Inc., as well as Pfizer’s pipeline and actions to enhance shareholder value, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Attention, those of you who own Pfizer Inc. (PFE): PFE has completed a spinoff of a new company, Viatris Inc. (VTRS). The transaction also gave the big drugmaker a $12 billion cash windfall that it can put to good use. Viatris (VTRS) will begin trading on November 17, 2020. Even with the company's headwinds, its revenue should be relatively stable throughout the first half of the decade and potentially grow in the second half. As noted in that earnings release, the total company guidance included full-year contributions from Upjohn; in light of the distribution of the Upjohn business and its combination with Mylan to form Viatris in mid-November 2020, the 2020 financial guidance overstates expected total company results. The company expects the “when-issued” market for Viatris common stock (VTRSV) to be available from Nov. 12 to Nov. … As of the closing of the combination, Pfizer stockholders owned approximately 57% of the outstanding shares of Viatris common stock, and Mylan shareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. Pfizer has been advised by Nasdaq that a “when-issued” market for Viatris common stock will exist beginning on November 12, 2020, the date that is the business day immediately prior to the record date for the spin-off, and continuing until the close of business on the expected closing date of November 16, 2020. That's a lot better than Pfizer's current yield of around 4.2%. DOW 31,402.01. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. [email protected]. Pfizer recently completed a spin-off of it's Upjohn business, combining it with Mylan N.V. to form a new entity, Viatris, which began trading on 11/16/2020 under the ticker symbol VTRS. Viatris began normal trading on November 16, 2020. Stocks fall as yields continue to climb; GameStop surges. 1. In the distribution, Pfizer stockholders received approximately 0.124079 shares of Viatris common stock for every one share of Pfizer common stock held as of the close of business on the record date (which was November 13, 2020). In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Unfortunately, neither Mylan nor Upjohn brought enough products with fast-rising sales to overcome these challenges right out of the gate. I don't think so. Should Pfizer shareholders sell their Viatris stock? Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. I waited a couple of weeks before posting this, because I wanted to be sure that every brokerage will settle this situation. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. I owned 75 shares of PFE before the spinoff, and 0 shares of Mylan. However, Viatris will have those drugs in its lineup. Spinoff of Viatris (VTRS) from Pfizer (PFE) Pfizer spun off its Upjohn unit which immediately merged with Mylan to form Viatris, effective November 16, 2020 in a transaction meant to be tax-free to Pfizer shareholders. Reply. Every time the stock rallied above $40, the market would find a reason to sell. The reality is that there isn't a universal answer about whether or not you should sell or hold Viatris stock. Before you log into your online brokerage or call your stockbroker to sell Viatris, it's important to note there's a good reason to hang onto your shares. Pfizer (NYSE: PFE) expects common stock for its Viatris spin-off to be available starting Nov. 12, following the U.S. Federal Trade Commission’s approval of the proposed merger of Mylan (NSDQ: MYL) and Pfizer’s biopharmaceutical Upjohn brand.. Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan, MAINTAINING EMOITONAL WELLBEING DURING COVID-19, CORONAVIRUS DISEASE (COVID-19) SCIENTIFIC RESOURCES. The stock spent much of the last half-decade (since 2016) in the $30 to $35 range. Latest spinoffs on the US stock market. This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial … I suspect that many Pfizer shareholders bought the stock in large part because of its strong dividend. The combined company was renamed Viatris in connection with the closing. Around Nov 18th I got 9 shares of VTRS and some change (around $5). It is common for the stock price of … And the company's business model should enable it to generate reliable cash flows. [email protected], Investor Relations It depends on your investing goals. If you're on the fence, perhaps the best thing to do is wait a while before making a decision. NEW YORK--(BUSINESS WIRE)-- level 2. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Report Save. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments. I want to express my gratitude to our Upjohn colleagues for their dedication in helping us achieve this milestone. VTRS stock will likely benefit from the upcoming Viatris restructuring program that seeks to eliminate $1 billion in … Pfizer intends to provide its initial 2021 financial guidance in conjunction with its fourth quarter 2020 earnings release, consistent with past practice. Forward-Looking Statements of Pfizer Inc. Pfizer's () long-awaited deal is finally done. Here's the kicker: Viatris intends to return a minimum of 25% of free cash flow to shareholders through its dividends. DISCLOSURE NOTICE: The information contained in this release is as of November 16, 2020. Last week, the big drugmaker completed its merger of Upjohn with Mylan. On the other hand, income-seeking investors will probably love Viatris. Mylan UpJohn Merger has been completed on 16th November 2020. If you're in that group, you might absolutely love Viatris. S&P 500 3,829.34. Factors that could cause actual results to differ materially from past results and future plans and projected future results are described in our Form 8-K furnished with the U.S. Securities and Exchange Commission on January 12, 2021 and linked here, which also contains information regarding our use of preliminary financial guidance. Of course, they haven't received market-beating returns from Pfizer in recent years, either. World shares skid, US futures turn higher after Wall St rout. Could this be a situation where Viatris starts out with a great dividend but has to cut it down the road? A spinoff happens when a company splits part of itself into a new independent company. Mylan N.V. was delisted from the Nasdaq stock exchange as a result of this corporate action and is no longer tradeable. Bryan Dunn A new REIT is coming shortly to sate investor’s income needs. There's continued price erosion for generic drugs in the U.S. China's volume-based procurement program is creating pricing pressure. It clears the path for Pfizer to return to solid growth. The stock fell 0.92 percent on Nov. 16 and closed at $16.19. The forward-looking statements in the webcast speak only as of the original date of the webcast. My cost basis is $17.11 for VTRS and I was wondering how was it calculated? The cost basis cannot be calculated until AFTER the spinoff takes place because, under IRS rules, the allocation is calculated based on relative fair market values of both the Parent company and Spinco after the spinoff is completed (usually based on the average high and low trading prices of both securities after the spinoff and reported on IRS Form 8937) . Viatris' bottom line should improve throughout the period as it realizes cost synergies. Creating Cures Through Facility Investments, Scaling Up to Supply a COVID-19 Vaccine, If Approved, https://www.businesswire.com/news/home/20201116005378/en/. Share. Under the terms of the transaction, which was structured as an all-stock Reverse Morris Trust, Upjohn Inc. was spun off to Pfizer stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan. Returns as of 03/02/2021. Amy Rose Pfizer will be able to deliver better growth going forward for one simple reason: It won't have older drugs such as Lyrica that are rapidly losing market share to generic alternatives weighing it down.